Rockwell Medical Announces Canadian Patent Issuance for Proprietary SFP-Iron Delivery

Rockwell Medical (NASDAQ: RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis, announced today that it has received notice from the Canadian Intellectual Property Office that it has obtained patent issuance for its proprietary drug, Soluble Ferric Pyrophosphate (SFP), the Company's late-stage investigational drug that provides iron replacement to hemodialysis patients with CKD.

Visit
www.marketwire.com/press-release/rockwell-medical-announces-canadian-patent-issuance-proprietary-sfp-iron-delivery-nasdaq-rmti-1674123.htm